Jack R. Andrews, MD; Eugene B. Cone MD; and Edwin Posadas, MD, FACP, discuss how early intervention with individualized treatment approaches based on disease volume, patient characteristics, and biomarkers significantly improves survival outcomes in metastatic hormone-sensitive prostate cancer.

1:35 Individualized Care for PC

9:24 Frailty & Comorbidities in PC

12:27 Molecular Testing in PC

18:10 Sequencing in PC

22:00 Doublets/Triplets in mHSPC

30:00 Subgroups in mHSPC

39:00 ARASENS Subgroup Analysis

43:55 Future of mHSPC Care